Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

Fig. 2

Headache days per month at baseline, weeks 8–12, weeks 20–24 and weeks 44–48 in the comparison between patients A) aged 65, B) concomitant use of OnabotA, C) daily headache at baseline, D) chronic painful syndromes, E) Fibromyalgia, and F) treatment resistance. Missing data is managed by baseline carried forward

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us